Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Kate Coldwell

Kate Coldwell

Kate Coldwell

PhD, PGCE


Daphne Jackson Trust Fellow

Disentangling the temporal interplay between the liver and gut in primary sclerosing cholangitis

Primary sclerosing cholangitis (PSC) is a rare liver disease with no effective treatment. Its aetiology is complex but likely involves links between the gut, gut microbiome and liver. To understand the disease better, we are studying markers of intestinal inflammation, intestinal permeability and microbiome-derived metabolites in the longitudinal DYNAMHIX in PSC study, asking 'how does disrupted bile flow in PSC affect the gut microbiome, and conversely, how does the disruption to the gut microbiome affect the liver?'